Antengene Corporation Limited Announces Positive Profit Alert for First Half of 2026
Key Highlights
- Massive Revenue Surge: Antengene Corporation expects revenue between RMB490 million and RMB536 million for the six months ended June 30, 2026, compared to just RMB53.2 million in the same period in 2025—a nearly tenfold increase.
- Turnaround to Profit: The company anticipates a net profit ranging from RMB195 million to RMB238 million for H1 2026, a dramatic turnaround from a loss of RMB76.4 million in H1 2025.
- Major Licensing Deals: The surge in revenue and profitability is primarily driven by two significant out-licensing and collaboration agreements:
- ATG-201 (CD19×CD3) Out-licensed to UCB: Effective from March 2026, this deal was the main revenue driver, with Antengene receiving an upfront payment of USD60 million from UCB.
- ATG-106 (CDH6×CD3) Out-licensed to K2 Therapeutics: Effective from June 2026, this agreement provided additional revenue during the reporting period.
- Preliminary Figures: These numbers are based on unaudited management accounts and are still subject to finalization and audit review.
- Interim Results Pending: The actual interim results will be published by the end of August 2026.
Implications for Shareholders and Investors
The substantial increase in revenue and the move from loss to profit are highly price-sensitive events. The company’s strategic focus on out-licensing key assets has resulted in significant upfront payments and new revenue streams, which could materially affect Antengene’s share value. The announcements of these deals, and the receipt of major upfront payments, represent pivotal moments for the company and its financial performance.
Investors should note that these are preliminary figures, and the final audited results may differ. The Board advises shareholders and potential investors to exercise caution when dealing in the company’s securities ahead of the publication of the official interim results.
Board and Corporate Governance
The announcement was authorized by Dr. Jay Mei, Chairman of Antengene Corporation Limited. The Board consists of executive directors Dr. Jay Mei and Mr. Donald Andrew Lung, and independent non-executive directors Ms. Jing Qian, Mr. Sheng Tang, and Dr. Rafael Fonseca.
Conclusion
Antengene Corporation’s positive profit alert marks a significant milestone for the company, reflecting successful execution of its licensing strategy and robust revenue growth. The anticipated turnaround in profitability and the impact of major deals are expected to be closely watched by market participants.
Disclaimer
This article is based on preliminary, unaudited financial information released by Antengene Corporation Limited. Final audited results will be published by the end of August 2026. Investors are advised to exercise caution and consult official disclosures before making investment decisions.
安天醫藥（Antengene）公佈2026年上半年正面盈利預告
重點摘要
- 收入激增：預計2026年上半年收入將達到人民幣4.9億至5.36億元，遠高於2025年同期的人民幣5320萬元，增幅近十倍。
- 由虧轉盈：公司預計2026年上半年淨利潤為人民幣1.95億至2.38億元，而2025年同期則錄得虧損7640萬元。
- 主要授權合作：收入及盈利大幅增長主要來自兩項重大授權協議：
- ATG-201（CD19×CD3）授權予UCB：協議於2026年3月生效，為主要收入來源，公司已收到UCB的6000萬美元首付款。
- ATG-106（CDH6×CD3）授權予K2 Therapeutics：協議於2026年6月生效，為公司帶來額外收入。
- 初步數據：以上數據基於未經審核的管理賬目，最終財務數據仍待審核。
- 中期業績即將公佈：最終中期業績將於2026年8月底公佈。
對股東及投資者的啟示
收入和盈利的大幅提升屬敏感信息，可能對股價產生重大影響。公司核心資產授權策略取得顯著成效，首付款和新增收入來源將直接影響安天醫藥的股價表現。相關合作和資金流入是公司發展的重要里程碑。
投資者需注意，以上數據為初步估算，最終審核結果可能有所變動。董事會建議股東及潛在投資者在正式業績公佈前，謹慎處理公司證券交易。
董事會及公司治理
本公告由董事會主席梅建明博士批准，董事會成員包括執行董事梅建明博士、Donald Andrew Lung先生，以及獨立非執行董事錢婧女士、唐晟先生及Rafael Fonseca博士。
總結
安天醫藥正面盈利預告標誌公司階段性成功，反映授權策略和收入增長卓有成效。盈利由虧轉盈及重大合作協議的影響，預計將成為市場關注焦點。
免責聲明
本文章根據安天醫藥公佈的初步、未經審核之財務資料整理，最終審核結果將於2026年8月底公佈。投資者應謹慎行事，並於作出投資決策前參閱公司正式披露資料。
